Drug Companies Are Sitting on Generics—43% of Recently Approved Aren’t for Sale
Posting for that friend who loves to tell me that Trump and capitalism will find a way to produce needed drugs and make them cheaper… There are huge markets going untapped, and stagnant pools of decades old capital out there, but these drugs are not being made.
nalysis by Kaiser Health News.
The finding means that many pricy, brand-name drugs are not facing the competition that could help drive down soaring prices. Among the drugs missing in action are generic versions of the expensive blood thinner Brilinta and the HIV medication Truvada. Moreover, of the approved drugs that would offer a brand-name drug its first competition, 36 percent are being held off the market, the analysis found.
Ars Technicaclose dialogJoin Ars Technica andGet Our Best Tech StoriesDelivered Straight to your Inbox.Please enter aboveSIGN ME UPWill be used in accordance with ourPrivacy PolicyThanks!You Are Successfully Subscribedclose dialog/* effects for .bx-campaign-813594 *//* custom css .bx-campaign-813594 *//* custom css from creative 30884 */.bx-custom.bx-campaign-813594 #bx-element-813594-KmYHkpO { vertical-align: top;}/* rendered styles .bx-campaign-813594 */.bxc.bx-campaign-813594.bx-active-step-1 .bx-creative> *:first-child {width: 680px;padding: 20px 0 45px;}@media all and (max-width: 736px) {.bxc.bx-campaign-813594.bx-active-step-1 .bx-creative> *:first-child {width: 345px;}}.bxc.bx-campaign-813594.bx-active-step-1 .bx-creative:before {min-height: 290px;}@media all and (max-width: 736px) {.bxc.bx-campaign-813594.bx-active-step-1 .bx-creative:before {min-height: 310px;}}.bxc.bx-campaign-813594 .bx-group-813594-rQWiaQ5 {padding: 0 0 15px;}.bxc.bx-campaign-813594 .bx-element-813594-ICDTsc2 {padding: 0;}.bxc.bx-campaign-813594 .bx-element-813594-ICDTsc2> *:first-child {height: 40px;background-color: transparent;background-size: contain;padding: 0;}.bxc.bx-campaign-813594 .bx-group-813594-9V7DjRk {width: 100%;padding: 0;}@media all and (max-width: 736px) {.bxc.bx-campaign-813594 .bx-group-813594-9V7DjRk {width: 100%;}}.bxc.bx-campaign-813594 .bx-element-813594-eLuSF9U {padding: 0 0 6px;}@media all and (max-width: 736px) {.bxc.bx-campaign-813594 .bx-element-813594-eLuSF9U {width: auto;}}.bxc.bx-campaign-813594 .bx-element-813594-eLuSF9U> *:first-child {font-size: 16px;}@media all and (max-width: 736px) {.bxc.bx-campaign-813594 .bx-element-813594-eLuSF9U> *:first-child {font-size: 14px;}}.bxc.bx-campaign-813594 .bx-element-813594-nNHNozp {width: 100%;padding: 0 0 8px;}.bxc.bx-campaign-813594 .bx-element-813594-nNHNozp> *:first-child {font-size: 36px;}@media all and (max-width: 736px) {.bxc.bx-campaign-813594 .bx-element-813594-nNHNozp> *:first-child {font-size: 23px;}}@media all and (max-width: 736px) {.bxc.bx-campaign-813594 .bx-element-813594-IMQMdcF {width: auto;}}.bxc.bx-campaign-813594 .bx-element-813594-IMQMdcF> *:first-child {font-size: 20px;}@media all and (max-width: 736px) {.bxc.bx-campaign-813594 .bx-element-813594-IMQMdcF> *:first-child {font-size: 12px;}}.bxc.bx-campaign-813594 .bx-group-813594-7Y4PFWQ {width: 430px;}@media all and (max-width: 736px) {.bxc.bx-campaign-813594 .bx-group-813594-7Y4PFWQ {width: 280px;padding: 10px 0 0 0;}}.bxc.bx-campaign-813594 .bx-element-813594-VYWXDZZ {width: 60%;}@media all and (max-width: 736px) {.bxc.bx-campaign-813594 .bx-element-813594-VYWXDZZ {width: 100%;}}.bxc.bx-campaign-813594 .bx-element-813594-KmYHkpO {width: 40%;}@media all and (max-width: 736px) {.bxc.bx-campaign-813594 .bx-element-813594-KmYHkpO {width: 100%;}}.bxc.bx-campaign-813594 .bx-element-813594-KmYHkpO> *:first-child {height: 42px;}.bxc.bx-campaign-813594 .bx-group-813594-B6Hxp6I {width: 100%;padding: 0;position: absolute;bottom: 5%;left: 0;}.bxc.bx-campaign-813594 .bx-element-813594-PqlU3Cr {width: auto;padding: 0 3px 0 0;}.bxc.bx-campaign-813594 .bx-element-813594-PqlU3Cr> *:first-child {padding: 0;}.bxc.bx-campaign-813594 .bx-element-813594-XAmqvwI {width: auto;padding: 0;}.bxc.bx-campaign-813594 .bx-element-813594-XAmqvwI> *:first-child {padding: 0;}.bxc.bx-campaign-813594.bx-active-step-2 .bx-creative> *:first-child {width: 680px;padding: 20px 0 40px;}@media all and (max-width: 736px) {.bxc.bx-campaign-813594.bx-active-step-2 .bx-creative> *:first-child {width: 345px;}}.bxc.bx-campaign-813594.bx-active-step-2 .bx-creative:before {min-height: 290px;}@media all and (max-width: 736px) {.bxc.bx-campaign-813594.bx-active-step-2 .bx-creative:before {min-height: Plus, access to our premium forums. ;}}.bxc.bx-campaign-813594 .bx-group-813594-VnlQ1Q6 {padding: 0;}.bxc.bx-campaign-813594 .bx-element-813594-wuBSHw3 {padding: 0;}.bxc.bx-campaign-813594 .bx-element-813594-wuBSHw3> *:first-child {height: 40px;background-color: transparent;background-size: contain;padding: 0;}.bxc.bx-campaign-813594 .bx-group-813594-YytTDny {width: 100%;padding: 20px 0 0 0;}@media all and (max-width: 736px) {.bxc.bx-campaign-813594 .bx-group-813594-YytTDny {width: 100%;}}.bxc.bx-campaign-813594 .bx-element-813594-73sFtao {padding: 0 0 6px;width: 100%;}@media all and (max-width: 736px) {.bxc.bx-campaign-813594 .bx-element-813594-73sFtao {width: auto;}}.bxc.bx-campaign-813594 .bx-element-813594-73sFtao> *:first-child {font-size: 16px;}@media all and (max-width: 736px) {.bxc.bx-campaign-813594 .bx-element-813594-73sFtao> *:first-child {font-size: 14px;}}.bxc.bx-campaign-813594 .bx-element-813594-YJNA5ZQ {width: 370px;padding: 0 0 8px;}@media all and (min-width: 737px) and (max-width: 1024px) {.bxc.bx-campaign-813594 .bx-element-813594-YJNA5ZQ {padding: 0 0 8px;}}.bxc.bx-campaign-813594 .bx-element-813594-YJNA5ZQ> *:first-child {font-size: 36px;}@media all and (max-width: 736px) {.bxc.bx-campaign-813594 .bx-element-813594-YJNA5ZQ> *:first-child {font-size: 23px;}}@media all and (min-width: 737px) and (max-width: 1024px) {.bxc.bx-campaign-813594 .bx-element-813594-YJNA5ZQ> *:first-child {font-size: 30px;}}.bxc p { line-height: inherit; font: inherit;}.bxc h2 { margin: 0;}.bxc#bx-campaign-813594, .bxc#bx-campaign-813594 .bx-slab { display: block !important; }
Experts told KHN that the reasons drug makers may withhold an approved generic from the market are varied. Industry consolidation has made buying, manufacturing, and distributing generics more difficult in recent years. Generic drug makers also, as always, face patent litigation from brand-name makers. Then there’s potentially anti-competitive deals, in which brand-name drug makers simply pay generic makers to keep their product off the market for a while—a so-called “pay for delay” tactic.
More: Drug companies are sitting on generics—43% of recently approved aren’t for sale